Abbott to preview molecular diagnostic system

Abbott Molecular says it will preview its new automated molecular diagnostics system this week.

Tests for HIV-1 and hepatitis-C and hepatitis-B viruses have been launched in Europe using the m2000 system, as well as a combined test for chlamydia and gonorrhoea. The technology is based on real-time polymerase chain reaction (PCR) technology, allowing infectious diseases to be monitored and detected by using a fully-automated system.

PCR is a method of copying DNA or RNA so it becomes easier to read, meaning it can be analysed more quickly and with greater accuracy.

The m2000 system combines an automated sample preparation system, which eliminates time-consuming manual processes like pipetting, with the m2000rt real-time PCR amplification and detection equipment and software. The system includes an “open mode” testing option to allow real-time testing with (PCR) components and reagents.

Edward Michael, president of Abbott Molecular, remarked: “The m2000 has been designed to help our customers deliver patient test results quickly and efficiently, with extremely accurate results.”

“This innovative system represents our continued commitment to accelerate automation for the clinical molecular laboratory and improve the diagnosis, monitoring and care of patients with infectious diseases and other serious illnesses,” he added.

Abbott Molecular Diagnostics features in the UK’s diagnostic industry. Abbott UK takes in over 700 million pounds each year in revenues and exports to 70 countries. It employs some 3,000 staff and has three UK manufacturing sites, in Queensborough, Witney and Dartford.

© Adfero Ltd